Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesOncolytics Biotech Inc

Oncolytics Biotech Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None CAD 0.00(0%)
Last update at 2025-09-04T20:00:41.784561Z
Market Cap
82.60M

Momentum Score

…

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.45
Low
2.08
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
14.90
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.02
ROE
-213.85%
Net Debt
-31.11M
ROCE
-211.62%
Diluted EPS TTM
-0.40

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -24.75M -26.25M -22.51M -33.12M -16.49M
Net income -24.84M -26.30M -16.72M -58.16M -17.04M
Selling general administrative 11.49M 4.28M 1.52M 0.91M 1.01M
Gross profit - - - - 0.00M
Reconciled depreciation 0.39M 0.45M 0.45M 0.49M 0.10M
Ebit -28.57M -26.23M -25.46M -20.69M -16.32M
Ebitda -28.18M -25.66M -27.85M -7.60M -16.22M
Depreciation and amortization 0.39M 0.57M -2.39M 13.09M 0.10M
Operating income -28.57M -26.23M -25.46M -20.69M -16.66M
Other operating expenses 26.92M 26.23M 25.46M 20.69M 16.66M
Interest expense 0.53M 0.10M 0.00M 0.32M 0.17M
Tax provision 0.08M 0.05M 0.00M 0.00M 0.55M
Interest income 0.53M 0.02M 0.12M 12.43M 0.17M
Net interest income 0.53M 0.10M 0.12M 0.18M 0.17M
Income tax expense 0.08M 0.05M -5.79M 25.04M 0.55M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 26.92M 26.23M 25.46M 20.69M 16.66M
Cost of revenue - - - - 0.00M
Total other income expense net 3.82M -0.02M 2.95M -12.43M 0.17M
Net income from continuing ops -24.84M -26.30M -22.51M -33.12M -17.04M
Net income applicable to common shares -24.84M -26.30M -22.51M -33.12M -17.04M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 20.19M 38.82M 37.33M 45.88M 34.35M
Other current assets - 3.25M 3.02M 2.78M -
Total liab 14.20M 11.26M 10.83M 9.78M 9.59M
Total stockholder equity 5.98M 27.56M 26.50M 36.10M 24.75M
Other current liab 1.62M 4.10M 1.48M 2.40M 2.46M
Common stock - 430.91M 404.04M 391.35M 356.82M
Capital stock 438.19M 430.91M 404.04M 391.35M 356.82M
Retained earnings -477.71M -446.00M -418.25M -393.42M -367.11M
Other liab - - 6.73M 6.73M 6.73M
Other assets - 0.00M 1.00M - -
Cash 15.94M 31.53M 11.67M 41.26M 31.22M
Cash and equivalents - - 11.67M 1.36M 0.86M
Total current liabilities 6.69M 4.24M 3.94M 2.69M 2.71M
Current deferred revenue - -1.08M - - -
Net debt - -31.11M -11.29M -40.61M -30.82M
Short term debt - 0.13M 0.22M 0.29M 0.25M
Short long term debt total - 0.42M 0.37M 0.65M 0.40M
Other stockholder equity - 42.12M 40.05M 37.78M 34.64M
Property plant equipment - - 0.65M 0.98M 0.61M
Total current assets 18.88M 38.17M 35.68M 44.90M 33.74M
Net tangible assets - - 26.50M 36.10M 24.75M
Short term investments - 3.38M 20.47M 39.90M 30.36M
Net receivables - 0.01M 0.52M 0.87M 0.09M
Accounts payable 1.09M 1.08M 2.25M 1.99M 1.81M
Accumulated other comprehensive income - 0.54M 0.66M 0.39M 0.40M
Common stock total equity - - - - 356.82M
Non currrent assets other - -0.00M 1.00M - -
Non current assets total 1.31M 0.65M 1.65M 0.98M 0.61M
Capital lease obligations 1.06M 0.42M 0.37M 0.65M 0.40M
Long term debt total - - 0.16M 0.36M 0.15M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -20.40M -0.29M -0.03M -0.01M -0.11M
Change to liabilities 1.66M 0.18M -1.37M 1.35M -1.31M
Total cashflows from investing activities -20.40M -0.29M -0.03M -0.01M -0.11M
Net borrowings -0.38M -0.37M -0.46M -0.45M -0.45M
Total cash from financing activities 12.21M 33.02M 39.77M 21.02M 13.30M
Change to operating activities -1.62M -0.31M -0.40M -1.13M 0.46M
Net income -24.84M -26.30M -22.51M -33.12M -17.04M
Change in cash -29.60M 10.04M 17.07M 0.45M 1.86M
Begin period cash flow 41.26M 31.22M 14.15M 13.70M 11.84M
End period cash flow 11.67M 41.26M 31.22M 14.15M 13.70M
Total cash from operating activities -23.36M -22.43M -22.07M -19.91M -11.92M
Issuance of capital stock 12.57M 32.91M 38.30M 18.00M 13.17M
Depreciation 0.39M 0.45M 0.45M 0.49M 0.10M
Other cashflows from investing activities -20.35M - - 0.00M 0.00M
Change to account receivables 0.34M -0.78M 1.98M -2.02M 4.77M
Sale purchase of stock 0.01M 0.47M 1.94M 13.33M 12.85M
Other cashflows from financing activities 0.01M 0.47M 1.94M 3.47M 0.12M
Change to netincome 0.70M 4.33M -0.22M 14.53M 1.12M
Capital expenditures 0.06M 0.29M 0.03M 0.01M 0.11M
Change in working capital 0.39M -0.91M 0.21M -1.80M 3.90M
Stock based compensation 2.38M 3.83M 2.56M 1.47M 1.42M
Other non cash items -1.68M 0.50M -2.78M 13.06M -0.30M
Free cash flow -23.41M -22.72M -22.10M -19.92M -12.03M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
EPRX
Eupraxia Pharmaceuticals Inc		 -0.17
1.76%		 9.48 - - - 8.45 -3.88
FRX
Fennec Pharmaceuticals Inc		 0.20
1.35%		 14.99 - 21.01 6.95 6.35 20.27
MSCL
Satellos Bioscience Inc.		 -
-%		 9.00 - - - 5.85 6.47
HBP
Helix BioPharma Corp.		 -0.10
9.80%		 0.92 - 3.87 4263.36 9.74 -6.36

Profile*

Oncolytics Biotech Inc

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.

322 11th Avenue SW, Calgary, AB, Canada, T2R 0C5

403-670-7377

https://oncolyticsbiotech.com

28

Name Title Year Born
Dr. Matthew C. Coffey M.B.A., Ph.D. Pres, CEO & Director NA
Mr. Kirk J. Look C.A., CA Chief Financial Officer NA
Mr. Andrew R. de Guttadauro Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc 1967
Dr. Thomas C. Heineman M.D., Ph.D. Chief Medical Officer NA
Ms. Allison Hagerman P.Eng., P.M.P. VP of Product Devel. NA
Jon Patton Director of Investor Relations & Communication NA
Dr. Grey Wilkinson Ph.D. Scientist of Translational Medicine NA
Mr. John Mark Lievonen F.C.A., FCA Consultant NA
Dr. Daniel Douglas Von Hoff F.A.C.P., FACP, M.D. Consultant 1948
Mr. Wayne F. Pisano M.B.A. Interim CEO & Chairman of the Board 1955

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…